Acceptability and compliance of atenolol tablet, compounded paste and compounded suspension prescribed to healthy cats*.
This study was designed to evaluate the cats' acceptance and compliance of the owners and cats towards an extemporaneously prepared palatable compounded atenolol (paste and suspension) formulation in comparison to the commercially obtained tablet, in a randomised, cross-over study design.The three formulations were prescribed twice daily for 6 days to 13 healthy privately-owned cats of 13 different owners, with varying levels of experience in medicating cats. Daily compliance was evaluated via an owner-completed diary, completed after each dose administered. Owner's experience and preference of the formulation was evaluated via questionnaires given prior to, at the end of each treatment protocol, and upon completion of the study. Although compounded suspension was association with fewest missed doses, the majority of cat owners expressed a preference for the divided tablet. Atenolol tablets, compounded paste and suspension acceptance and compliance were comparable. Further work is now required to assess the amount and stability of the active ingredient and the robustness of the paste and suspension formulations prior to any bioavailability comparisons between the formulations.
School of Veterinary Science, The University of Queensland, Gatton Campus, Queensland, Australia.
Kuan Hua
KH
Khor
Fiona
F
Campbell
Michael J
MJ
Rathbone
Ristan M
RM
Greer
Paul C
PC
Mills
D000284:Administration, Oral; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001262:Atenolol / Q000008:administration & dosage*; D001522:Behavior, Animal; D002415:Cats; D018592:Cross-Over Studies; D004339:Drug Compounding; D005260:Female; D008297:Male; D009824:Ointments; D019999:Pharmaceutical Solutions; D013607:Tablets
D000959:Antihypertensive Agents; D009824:Ointments; D019999:Pharmaceutical Solutions; D013607:Tablets; D001262:Atenolol